"CD52 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A small GPI-linked glycoprotein expressed on the surface of normal and malignant B-CELLS; T-CELLS; MONOCYTES; MACROPHAGES; NK CELLS; and GRANULOCYTES. It is expressed densely and without modulation in many malignant T-cell neoplasms and therefore a target for antibody therapies (e.g., ALEMTUZUMAB).
| Descriptor ID |
D000074301
|
| MeSH Number(s) |
D12.776.395.550.448.190 D12.776.543.484.500.190 D12.776.543.550.418.190 D23.050.285.022 D23.101.100.943
|
| Concept/Terms |
CD52 Antigen- CD52 Antigen
- CDw52 Antigen
- Campath-1 Antigen
- Campath 1 Antigen
- Campath-1H Antigen
- Campath 1H Antigen
- Lymphocyte Antigen CDw52
- CDw52, Lymphocyte Antigen
- Lymphocyte Antigen CD52
- CD52, Lymphocyte Antigen
- Campath-1 Receptor
- Campath 1 Receptor
- HLA-Bw52 Antigen
- HLA Bw52 Antigen
- HLA-Bw52
- HLA Bw52
- Cambridge Pathology 1 Antigen
- CD52 Protein
|
Below are MeSH descriptors whose meaning is more general than "CD52 Antigen".
Below are MeSH descriptors whose meaning is more specific than "CD52 Antigen".
This graph shows the total number of publications written about "CD52 Antigen" by people in this website by year, and whether "CD52 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 |
| 2018 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "CD52 Antigen" by people in Profiles.
-
Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. PLoS One. 2018; 13(7):e0199708.
-
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018 Jun; 24 Suppl 2:S71-S82.
-
Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma. 2008 Dec; 49(12):2256-62.